Farukh A. Durrani

1.5k total citations
49 papers, 1.2k citations indexed

About

Farukh A. Durrani is a scholar working on Pulmonary and Respiratory Medicine, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Farukh A. Durrani has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 22 papers in Biomedical Engineering and 19 papers in Molecular Biology. Recurrent topics in Farukh A. Durrani's work include Nanoplatforms for cancer theranostics (22 papers), Photodynamic Therapy Research Studies (16 papers) and Cancer, Hypoxia, and Metabolism (14 papers). Farukh A. Durrani is often cited by papers focused on Nanoplatforms for cancer theranostics (22 papers), Photodynamic Therapy Research Studies (16 papers) and Cancer, Hypoxia, and Metabolism (14 papers). Farukh A. Durrani collaborates with scholars based in United States, Canada and Australia. Farukh A. Durrani's co-authors include Youcef M. Rustum, Shousong Cao, Károly Tóth, Ravindra K. Pandey, Sreenivasulu Chintala, Arup Bhattacharya, Rami G. Azrak, Marwan Fakih, Lakshmi Pendyala and Joseph R. Missert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Farukh A. Durrani

49 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Farukh A. Durrani United States	21	458	369	333	290	263	49	1.2k
Qianqian Yu China	13	299 0.7×	175 0.5×	153 0.5×	168 0.6×	319 1.2×	45	1.1k
Jiřina Hofmanová Czechia	24	859 1.9×	182 0.5×	181 0.5×	114 0.4×	314 1.2×	82	1.5k
Peter Geiger United States	14	477 1.0×	145 0.4×	105 0.3×	158 0.5×	185 0.7×	30	969
Lakshmipathi Khandrika United States	10	719 1.6×	189 0.5×	101 0.3×	104 0.4×	190 0.7×	19	1.4k
Feiya Yang China	19	645 1.4×	285 0.8×	92 0.3×	256 0.9×	211 0.8×	70	1.5k
Mattia Zaccarin Italy	14	794 1.7×	600 1.6×	190 0.6×	78 0.3×	89 0.3×	21	1.3k
Keisei Okamoto Japan	21	1.6k 3.5×	300 0.8×	129 0.4×	96 0.3×	262 1.0×	40	2.5k
Qingbin Cui China	22	1.0k 2.3×	185 0.5×	56 0.2×	229 0.8×	679 2.6×	49	1.8k
Amit Deorukhkar United States	18	953 2.1×	121 0.3×	45 0.1×	339 1.2×	263 1.0×	34	1.8k
Gabriela M. Almeida Portugal	24	806 1.8×	233 0.6×	54 0.2×	92 0.3×	322 1.2×	38	1.6k

Countries citing papers authored by Farukh A. Durrani

Since Specialization

Citations

This map shows the geographic impact of Farukh A. Durrani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farukh A. Durrani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farukh A. Durrani more than expected).

Fields of papers citing papers by Farukh A. Durrani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farukh A. Durrani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farukh A. Durrani. The network helps show where Farukh A. Durrani may publish in the future.

Co-authorship network of co-authors of Farukh A. Durrani

This figure shows the co-authorship network connecting the top 25 collaborators of Farukh A. Durrani. A scholar is included among the top collaborators of Farukh A. Durrani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farukh A. Durrani. Farukh A. Durrani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Durrani, Farukh A., Zahra Fayazi, Adam B. Sumlin, et al.. (2023). Excitation of a Single Compound by Light and Ultrasound Enhanced the Long-Term Cure of Mice Bearing Prostate Tumors. International Journal of Molecular Sciences. 24(13). 10624–10624. 1 indexed citations

Durrani, Farukh A., et al.. (2022). Photodynamic Therapy in Combination with Doxorubicin Is Superior to Monotherapy for the Treatment of Lung Cancer. Biomedicines. 10(4). 857–857. 15 indexed citations

Durrani, Farukh A., Walter A. Tabaczynski, Penny Joshi, et al.. (2022). Impact of mono- and di-β-galactose moieties in in vitro / in vivo anticancer efficacy of pyropheophorbide-carbohydrate conjugates by photodynamic therapy. SHILAP Revista de lepidopterología. 5. 100047–100047. 2 indexed citations

Nwogu, Chukwumere, et al.. (2021). Porfimer Sodium Versus PS785 for Photodynamic Therapy (PDT) of Lung Cancer Xenografts in Mice. Journal of Surgical Research. 263. 245–250. 9 indexed citations

Srivatsan, Avinash, Paula Pera, Penny Joshi, et al.. (2020). Highlights on the imaging (nuclear/fluorescence) and phototherapeutic potential of a tri-functional chlorophyll-a analog with no significant toxicity in mice and rats. Journal of Photochemistry and Photobiology B Biology. 211. 111998–111998. 7 indexed citations

Durrani, Farukh A., B.M. Borah, Manivannan Ethirajan, et al.. (2019). Pluronic F‐127: An Efficient Delivery Vehicle for 3‐(1'‐hexyloxy)ethyl‐3‐devinylpyropheophorbide‐a (HPPH or Photochlor). Photochemistry and Photobiology. 96(3). 625–635. 14 indexed citations

Joshi, Penny, Tymish Y. Ohulchanskyy, Yihui Chen, et al.. (2016). Photosensitizer (PS)-cyanine dye (CD) conjugates: Impact of the linkers joining the PS and CD moieties and their orientation in tumor-uptake and photodynamic therapy (PDT). European Journal of Medicinal Chemistry. 122. 770–785. 23 indexed citations

Cao, Shousong, Farukh A. Durrani, Youcef M. Rustum, & Yichao Yu. (2012). Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity. Cancer Chemotherapy and Pharmacology. 69(4). 1107–1111. 6 indexed citations

Chintala, Sreenivasulu, Tanbir Najrana, Károly Tóth, et al.. (2012). Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC Cancer. 12(1). 293–293. 53 indexed citations

10.

Azrak, Rami G., Shousong Cao, Farukh A. Durrani, et al.. (2011). Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation. Cancer Letters. 311(2). 219–229. 12 indexed citations

11.

Chintala, Sreenivasulu, Károly Tóth, Arup Bhattacharya, et al.. (2010). Downregulation of Cystine Transporter x<sub>c</sub><sup>–</sup> by Irinotecan in Human Head and Neck Cancer FaDu Xenografts. Chemotherapy. 56(3). 223–233. 14 indexed citations

12.

Chintala, Sreenivasulu, Károly Tóth, Shousong Cao, et al.. (2010). Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α. Cancer Chemotherapy and Pharmacology. 66(5). 899–911. 60 indexed citations

13.

Bhattacharya, Arup, Károly Tóth, Arindam Sen, et al.. (2009). Inhibition of Colon Cancer Growth by Methylselenocysteine-Induced Angiogenic Chemomodulation Is Influenced by Histologic Characteristics of the Tumor. Clinical Colorectal Cancer. 8(3). 155–162. 28 indexed citations

14.

Durrani, Farukh A., Shousong Cao, Young‐Mee Park, et al.. (2007). Synergistic effect of selenium compounds with radiation therapy in human A549 lung xenografts. Cancer Research. 67. 750–750. 2 indexed citations

15.

Azrak, Rami G., Shousong Cao, Lakshmi Pendyala, et al.. (2006). Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochemical Pharmacology. 73(9). 1280–1287. 25 indexed citations

16.

Tóth, Károly, Shousong Cao, Farukh A. Durrani, et al.. (2006). Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis. Oncogene. 25(17). 2509–2519. 32 indexed citations

17.

Cao, Shousong, Farukh A. Durrani, & Youcef M. Rustum. (2005). Synergistic Antitumor Activity of Capecitabine in Combination with Irinotecan. Clinical Colorectal Cancer. 4(5). 336–343. 22 indexed citations

18.

Fakih, Marwan, Shousong Cao, Farukh A. Durrani, & Youcef M. Rustum. (2005). Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors. Clinical Colorectal Cancer. 5(2). 132–135. 45 indexed citations

19.

Antony, Smitha, Glenda Kohlhagen, Muthusamy Jayaraman, et al.. (2004). Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison. Molecular Pharmacology. 67(2). 523–530. 64 indexed citations

20.

Laar, Jan van, et al.. (1995). Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-l-aspartate in murine colon carcinoma no. 26. European Journal of Cancer. 31(6). 974–976. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact